Tizanidine for the treatment of intention myoclonus: A case series

Archives of Physical Medicine and Rehabilitation

Volumn 85, Issue 7, 2004, Pages 1125-1127

  Mukand, Jon A ^a,b,c,d   Giunti, Eugene J ^e  

^a Southern New England Rehabilitation Center   (United States)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d BROWN UNIVERSITY   (United States)

^e BOSTON UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Intention tremor; Myoclonus; Neurologic disorders; Rehabilitation; Tizanidine

Indexed keywords

TIZANIDINE;

ADOLESCENT; AGED; ANAMNESIS; ARTICLE; BLOOD PRESSURE MONITORING; CASE REPORT; CLINICAL FEATURE; DAILY LIFE ACTIVITY; DRUG EFFICACY; DRUG SAFETY; DRUG SCREENING; ELECTROCARDIOGRAM; FEMALE; FOLLOW UP; FUNCTIONAL ASSESSMENT; HOSPITAL ADMISSION; HOSPITAL PATIENT; HUMAN; HYPOTENSION; MALE; MITOCHONDRIAL ENCEPHALOMYOPATHY; MULTIPLE SCLEROSIS; MYOCLONUS; PHYSICAL EXAMINATION; REDUCTION; REHABILITATION CENTER; SEDATION; SIDE EFFECT; STROKE; TREATMENT WITHDRAWAL; ULTRASOUND;

ADOLESCENT; ADRENERGIC ALPHA-AGONISTS; AGED; CLONIDINE; FEMALE; HUMANS; MALE; MYOCLONUS;

EID: 3242659258     PISSN: 00039993     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.apmr.2003.09.006     Document Type: Article

References (14)

1. Haerer A. DeJong's the neurologic examination. 5th ed.:1992;408-409 Lippincott, Philadelphia
2. Adams R.D., Victor M., Ropper A.H. Principles of neurology companion handbook. 6th ed.:1999;94-113 McGraw-Hill, New York
3. Hammans S.R., Sweeney M.G., Hanna M.G., Brockington M., Morgan-Hughes J.A., Harding A.E. The mitochondrial DNA transfer RNALeu (UUR) A→G (3243) mutations a clinical and genetic study. Brain. 118:(Pt 3):1995;721-734
4. Nardin R.A., Jorns D.R. Mitochondrial dysfunction and neuromuscular disease. Muscle Nerve. 24:2001;170-191
5. Cohen B.H., Gold D.R. Mitochondrial myopathy in adults what we know so far. Cleve Clin J Med. 68:2001;625-642. [published erratum in: Cleve Clin J Med 2001;68:746]
6. Brown P., Ridding M.C., Werhahn K.J., Rothwell J.C., Marsden C.D. Abnormalities of the balance between inhibition and excitation in the motor cortex of patients with cortical myoclonus. Brain. 119:1996;309-317
7. Metz L. Multiple sclerosis symptomatic therapies. Semin Neurol. 18:1998;389-395
8. Coward D.M. Tizanidine neuropharmacology and mechanism of action. Neurology. 44:(Suppl):1994;6-11
9. Physician's desk reference. 54th ed.:2000;643-645 Medical Economics, Montvale. Zanaflex (tizanidine hydrochloride).
10. Augustinsson L.E., Eliasson T., Mannheimer C. Spinal cord stimulation in severe angina pectoris [abstract]. Stereotact Funct Neurosurg. 65:1995;136-141
11. Jackson M.J., Schaefer J.A., Johnson M.A., Morris A.A., Turnbull D.M., Bindoff L.A. Presentation and clinical investigation of mitochondrial respiratory chain disease. A study of 51 patients. Brain. 118:(Pt 2):1995;339-357
12. Smith H.S., Barton A.E. Tizanidine in the management of spasticity and musculoskeletal complaints in the palliative care population. Am J Hosp Palliat Care. 17:2000;50-58
13. Snodgrass S.R. Myoclonus analysis of monoamine, GABA, and other systems [abstract]. FASEB J. 4:1990;2775-2788
14. Wallace J.D. Summary of combined clinical analysis of controlled clinical trials with tizanidine. Neurology. 44:(11 Suppl 9):1994;S60-S68. discussion S68-9